U.S. healthcare conglomerate Danaher Corp DHR.N said it will buy Nobel Biocare Holding AG NOBN.S in an all-cash deal valued at about $2.2 billion, including debt, to widen its market presence in the global dental industry. Danaher said it will offer 17.10 Swiss francs per Nobel Biocare share, representing a 7 percent premium to the current 60 day volume weighted average share price and a 28 percent VWAP premium before July 29, when Nobel Biocare said it was in early stage talks over a potential sale.